Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents
- PMID: 2109581
- PMCID: PMC171583
- DOI: 10.1128/AAC.34.2.337
Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents
Abstract
Some enteric bacteria, such as Enterobacter cloacae, can develop high-level resistance to broad-spectrum cephalosporins by overproducing their chromosomally encoded type I beta-lactamases. This is because these agents are hydrolyzed rapidly at pharmacologically relevant, low (0.1 to 1 microM), concentrations, owing to their high affinity for type I enzymes. In contrast, the more recently developed cephalosporins, with quaternary-nitrogen-containing substituents at the 3 position, show increased efficacy against beta-lactamase-overproducing strains and, indeed, have a much lower affinity for type I enzymes. However, the possible contribution of an improved outer membrane permeability in their increased efficacy has not been studied. We found by proteoliposome swelling assays that cefepime, cefpirome, and E-1040 all penetrated the porin channels of Escherichia coli and E. cloacae much more rapidly than did ceftazidime and at least as rapidly as did cefotaxime. Considering that the influx of anionic compounds such as cefotaxime and ceftazidime will be further retarded in intact cells, owing to the Donnan potential, we expect that the newer compounds will penetrate intact cells 2 to 10 times more rapidly than will cefotaxime and ceftazidime. The kinetic parameters of hydrolysis of these agents by E. cloacae beta-lactamase showed that at 0.1 microM, they were hydrolyzed much more slowly than was cefotaxime and at about the same rate as or a lower rate than was ceftazidime. The combination of these two effects explains nearly quantitatively why these newer agents are more effective against some of the beta-lactamase-overproducing gram-negative bacteria.
Similar articles
-
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.Antimicrob Agents Chemother. 1989 Apr;33(4):498-502. doi: 10.1128/AAC.33.4.498. Antimicrob Agents Chemother. 1989. PMID: 2499250 Free PMC article.
-
Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.Antimicrob Agents Chemother. 1986 May;29(5):845-8. doi: 10.1128/AAC.29.5.845. Antimicrob Agents Chemother. 1986. PMID: 3524432 Free PMC article.
-
Mechanism of inhibition of chromosomal beta-lactamases by third-generation cephalosporins.Rev Infect Dis. 1988 Jul-Aug;10(4):752-60. doi: 10.1093/clinids/10.4.752. Rev Infect Dis. 1988. PMID: 3142012
-
Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins.J Antimicrob Chemother. 1992 Apr;29 Suppl A:1-6. doi: 10.1093/jac/29.suppl_a.1. J Antimicrob Chemother. 1992. PMID: 1601751 Review.
-
[Specificities of antibacterial activity of zwitterionic 7-methoxyimino cephems (cephalosporins of fourth generation].Pathol Biol (Paris). 1996 Feb;44(2):99-105. Pathol Biol (Paris). 1996. PMID: 8761594 Review. French.
Cited by
-
β-Lactams and β-Lactamase Inhibitors: An Overview.Cold Spring Harb Perspect Med. 2016 Aug 1;6(8):a025247. doi: 10.1101/cshperspect.a025247. Cold Spring Harb Perspect Med. 2016. PMID: 27329032 Free PMC article. Review.
-
Cephalosporin resistance, tolerance, and approaches to improve their activities.J Antibiot (Tokyo). 2024 Mar;77(3):135-146. doi: 10.1038/s41429-023-00687-y. Epub 2023 Dec 19. J Antibiot (Tokyo). 2024. PMID: 38114565 Review.
-
Differential effects of bismuth and salicylate salts on the antibiotic susceptibility of Pseudomonas aeruginosa.Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):170-5. doi: 10.1007/BF01967072. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1396732
-
Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.Antimicrob Agents Chemother. 1997 Nov;41(11):2424-7. doi: 10.1128/AAC.41.11.2424. Antimicrob Agents Chemother. 1997. PMID: 9371344 Free PMC article. Clinical Trial.
-
A drug-resistant β-lactamase variant changes the conformation of its active-site proton shuttle to alter substrate specificity and inhibitor potency.J Biol Chem. 2020 Dec 25;295(52):18239-18255. doi: 10.1074/jbc.RA120.016103. Epub 2020 Oct 26. J Biol Chem. 2020. PMID: 33109613 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources